Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...
Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...
GlobalData on MSN1d
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drugThe primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.
Here's why Chicago is expected to be a growth spot for life sciences in the coming years. Chicago is expected to be a ...
Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...
By engaging with some of the most influential executives in the industry and the many organizations that advocate for them, the series will provide valuable perspectives on the evolving landscape of ...
AscellaHealth has introduced its latest initiative, the AscellaHealth Podcast Pulse, a platform delving into the critical ...
Healthcare & Life Sciences Private Equity Deal Tracker: Northlane Sells PAR Excellence to OceanSound
Northlane Capital Partners (NCP) has announced the sale of PAR Excellence Systems to OceanSound Partners. PAR Excellence, founded in 1992 and based in Cincinnati, is a provider of supply chain ...
Projects focus on cancer therapies, robotic clot removal catheters, and mRNA vaccines, among other technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback